Search research articles
Contact Us
Filters
Showing results (181-190 of 190) with videos related to
Page
of 19
Sort By:
You have reached the last page of results.
This site can display upto 190 results.
Gerontology
|
May 8, 2008
Physical fitness and cognitive function in an 85-year-old community-dwelling population
Y Takata, T Ansai, I Soh, et al.
Journal of Gastroenterology and Hepatology
|
May 8, 2001
Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells
A Ito, T Kanto, N Kuzushita, et al.
Oral Diseases
|
June 24, 2006
Dynamic magnetic resonance sialography as a new diagnostic technique for patients with Sjögren's syndrome
Y Morimoto, M Habu, T Tomoyose, et al.
Journal of Viral Hepatitis
|
May 20, 2016
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies
M Mizokami, H Dvory-Sobol, N Izumi, et al.
Cell Death and Differentiation
|
July 14, 2012
Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages
T Kodama, H Hikita, T Kawaguchi, et al.
Journal of Viral Hepatitis
|
August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1
T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis
|
August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
Y Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
N Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
N Hiramatsu, T Oze, T Yakushijin, et al.
Page
of 19
Search research articles
Search
Showing results (181-190 of 190) with videos related to
Sort By:
Page
of 19
You have reached the last page of results.
This site can display upto 190 results.
Gerontology
|
May 8, 2008
Physical fitness and cognitive function in an 85-year-old community-dwelling population
Y Takata, T Ansai, I Soh, et al.
Journal of Gastroenterology and Hepatology
|
May 8, 2001
Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells
A Ito, T Kanto, N Kuzushita, et al.
Oral Diseases
|
June 24, 2006
Dynamic magnetic resonance sialography as a new diagnostic technique for patients with Sjögren's syndrome
Y Morimoto, M Habu, T Tomoyose, et al.
Journal of Viral Hepatitis
|
May 20, 2016
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies
M Mizokami, H Dvory-Sobol, N Izumi, et al.
Cell Death and Differentiation
|
July 14, 2012
Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages
T Kodama, H Hikita, T Kawaguchi, et al.
Journal of Viral Hepatitis
|
August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1
T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis
|
August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
Y Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
N Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
T Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
N Hiramatsu, T Oze, T Yakushijin, et al.
Page
of 19